Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Deferred Revenue (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Current Deferred Revenue data on record, last reported at $360000.0 in Q2 2025.

  • For Q2 2025, Current Deferred Revenue fell 54.89% year-over-year to $360000.0; the TTM value through Jun 2025 reached $360000.0, down 54.89%, while the annual FY2024 figure was $660000.0, 33.27% down from the prior year.
  • Current Deferred Revenue reached $360000.0 in Q2 2025 per SNTI's latest filing, down from $513000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.7 million in Q4 2021 and bottomed at $99000.0 in Q3 2022.
  • Average Current Deferred Revenue over 5 years is $665000.0, with a median of $649500.0 recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: tumbled 80.31% in 2023, then surged 386.59% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.7 million in 2021, then plummeted by 94.02% to $99000.0 in 2022, then soared by 898.99% to $989000.0 in 2023, then plummeted by 33.27% to $660000.0 in 2024, then plummeted by 45.45% to $360000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $360000.0 in Q2 2025, $513000.0 in Q1 2025, and $660000.0 in Q4 2024.